[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"soft-tissue-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:soft-tissue-infections":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,72,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100625733","delafloxacin-plasma-and-tissue-concentration-in-patients-with-skin-soft-tissue-and-bone-and-joint-infections-100625733",false,"NCT07426471","Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections.","Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections: a Prospective Mono-center Observational Pharmacological Study.","DELA-PLAT","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study, and to be concurrently enrolled in the Institutional Infectious Disease Biobank (INDI-REBIO, NCT06418048)\n* \\>18 years-old\n* eGFR of \\> 80 mL\u002Fmin\u002F1,73m2\n* Receiving delafloxacin 300mg q12h IV according to treating physician's choice and good clinical practice or available guidelines with bacterial skin and skin structure infection and with\n\n  1. post-sternotomy wound infection and\u002For mediastinitis undergoing surgical debridement\n  2. prosthetic joint infections undergoing surgical debridement or prosthetic joint removal (either one-stage, e.g. when the Infected prosthesis is removed and a new one is implanted in the same surgery, or two-stage, when the Infected prosthesis is removed, followed by a period of antibiotics, then a new prosthesis is implanted in a second surgery).\n\nExclusion criteria:\n\n* Patients who received other quinolones (oral or IV) in the week preceding the sample collection\n* Patients who decline or are unwilling to participate in serial blood draws at all five designated time points.\n* Pregnant or lactating women","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","1 Day","OBSERVATIONAL","The goal of this observational study is to measure how well the antibiotic delafloxacin penetrates into the blood and various body tissues in adult patients over 18 years old. Specifically, this study focuses on patients who are receiving the drug to treat bacterial infections and are undergoing surgery for post-sternotomy wound infections, mediastinitis, or infected prosthetic joints .\n\nThe main questions it aims to answer are:\n\n* What is the concentration of delafloxacin in the blood plasma?\n* What is the concentration of delafloxacin in different body tissues, including soft tissue, tissue around a prosthetic implant, joint fluid (synovial fluid), and bone ?\n* How does the concentration of the drug in the blood compare to its concentration in the tissues?\n* Do patient factors such as age, body weight, and kidney function affect the drug's levels in the body?\n\nParticipants will:\n\n* Continue to receive delafloxacin (300mg intravenously every 12 hours) as prescribed by their treating physician for their infection.\n* Allow researchers to draw 5 peripheral blood samples (about 10 mL total) at specific times (15 minutes, 1 hour, 3 hours, 5-7 hours, and 11 hours) after the end of a single delafloxacin infusion.\n* Allow researchers to collect small amounts of tissue and joint fluid for testing during their already planned surgical procedure.",[26,27,28,29],"Soft Tissue Infections","Mediastinitis","Osteomyelitis\u002FSeptic Arthritis","Prosthetic Joint Infection","NOT_YET_RECRUITING","2026-02-20",{"date":33,"type":34},"2026-02-23","ACTUAL",{"date":36,"type":21},"2026-04-01",{"date":38,"type":21},"2027-01-31",{"name":40,"class":41},"IRCCS San Raffaele","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":5},"100620594","fatal-nsti-study-factors-associated-with-in-hospital-mortality-in-nsti-100620594","NCT07359651","FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI).","Factors Associated With In-hospital Mortality in Necrotizing Soft Tissue Infections. A Multicenter Retrospective Cohort Study. FATAL-NSTI Study (Factors Associated With In-hospital mortALity in NSTI).","FATAL-NSTI","Inclusion Criteria:\n\n* Age 18 years or older\n* Hospital admission with a diagnosis of necrotizing soft tissue infection, including: Necrotizing fasciitis, Fournier's gangrene, Necrotizing soft tissue infections involving the neck or trunk.\n\nExclusion Criteria:\n\n* Age younger than 18 years\n* Patients with non-necrotizing skin or soft tissue infections\n* Patients transferred to another hospital before completion of treatment or outcome assessment\n* Missing data for the primary outcome (in-hospital mortality)",{"count":51,"type":21},300,"Necrotizing soft tissue infections (NSTIs) are rare but potentially life-threatening infections involving the skin and underlying tissues such as fat, fascia, and sometimes muscle. They can progress rapidly and, despite modern antibiotics, surgery, and intensive care, are still associated with high in-hospital mortality.\n\nA major challenge in the management of NSTIs is early diagnosis. Initial signs and symptoms are often nonspecific and may resemble less severe soft tissue infections, leading to diagnostic and therapeutic delays. Once identified, treatment requires urgent surgery, broad-spectrum antibiotics, and close monitoring, frequently in an intensive care setting.\n\nEven with appropriate treatment, the clinical course of NSTIs is highly variable. Some patients recover, while others develop severe complications such as septic shock or multiple organ failure and may die during hospitalization. Predicting outcomes early in the hospital stay remains difficult for clinicians.\n\nThe aim of this observational study is to identify factors associated with in-hospital mortality in adult patients with NSTIs. In-hospital mortality, defined as death from any cause during the hospital stay for NSTI treatment, represents the most severe outcome and is of major relevance to patients and caregivers.\n\nThe study focuses on clinical and laboratory data routinely available at hospital admission or during initial emergency department evaluation. These include patient demographics, vital signs, and standard blood test results commonly obtained in early clinical assessment. No additional diagnostic tests or procedures are required for study purposes.\n\nIdentifying early predictors of mortality is particularly important in NSTIs, given the rapid progression of the disease. Early recognition of high-risk patients may allow closer monitoring and more timely interventions.\n\nThe study will be conducted in high-volume referral centers with extensive experience in NSTIs management, where care is delivered according to established international guidelines. All patients will receive standard treatment based on clinical judgment. No experimental therapies or changes in routine care will be involved.",[54,55,56,26],"Necrotizing Fascitis","Fournier Gangrene","Fournier's Gangrene",[58,59,60,61],"Necrotizing soft tissues infections","NSTI","Necrotizing fasciitis","Fournier's gangrene","RECRUITING","2026-01-15",{"date":65,"type":34},"2026-01-22",{"date":67,"type":34},"2020-01-01",{"date":69,"type":21},"2026-04-30",{"name":71,"class":41},"University of Cagliari",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":104},"100475513","follow-up-automatically-vs-as-needed-comparison-faan-c-trial-100475513","NCT05471908","Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial","The Follow-up Automatically vs. As-Needed Comparison Trial","FAAN-C","Inclusion Criteria:\n\n* Age \\\u003C18 years at the time of randomization\n* Hospitalization due to a primary diagnosis of pneumonia, skin and soft tissue infection, acute gastroenteritis, or urinary tract infection.\n* Parent speaks English or Spanish.\n\nExclusion Criteria:\n\n* Presence of a comorbid disease that is both chronic and complex\n* Principal disease required surgical intervention (beyond superficial incision and drainage)\n* Immunodeficiency\n* A well-child check-up or post-hospitalization follow-up visit is already scheduled within 7 days of hospital discharge\n* Parent or participant strongly prefers PRN or automatic follow-up\n* A medical provider feels strongly that a post-hospitalization follow-up visit is needed within 7 days of hospital discharge\n* Sibling concurrently hospitalized\n* Unable to identify a clinic where the participant would receive any needed post-hospitalization follow-up\n* Diagnosis of pneumonia complicated by:\n\n  o Receiving a chest tube\n* Diagnosis of urinary tract infection complicated by:\n\n  * History of neurogenic bladder or urologic surgery\n  * Renal imaging anticipated within 7 days of hospital discharge\n  * Renal abscess\n* Diagnosis of skin and soft tissue infection complicated by:\n\n  * Chronic wound\n  * Postoperative infection\n  * Predisposition to poor wound healing\n  * Discharging with a drain in place\n  * Complicated by necrotizing fasciitis or toxic shock syndrome\n* Diagnosis of gastroenteritis complicated by:\n\n  * Hemolytic uremic syndrome",{"count":81,"type":21},2674,"INTERVENTIONAL",[84],"NA","Compare the effectiveness of automatic vs as-needed (PRN) post-hospitalization follow-up for children who are hospitalized for common infections.",[87,88,26,89],"Pneumonia","Urinary Tract Infections","Gastroenteritis",[91,92,93,94],"post-hospitalization","follow-up care","patient centered care","randomized control trial","2025-12-03",{"date":97,"type":34},"2025-12-10",{"date":99,"type":34},"2022-08-22",{"date":101,"type":21},"2028-02-28",{"name":103,"class":41},"University of Utah",14,{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":111,"eligibilityCriteria":112,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":113,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":115,"conditions":116,"keywords":131,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":158},"100284234","fosfomycin-iv-for-treatment-of-severely-infected-patients-100284234","NCT02979951","Fosfomycin I.v. for Treatment of Severely Infected Patients","An International, Multicentre, Non-comparative, Non-interventional, Prospective Clinical Registry to Evaluate the Clinical Outcome and Safety of the Treatment of Severely Infected Patients with Fosfomycin I.v.","FORTRESS","Inclusion Criteria:\n\n* Male or female patients aged ≥ 18 years\n* Treatment with fosfomycin according to the (national) Summary of Product Characteristics (SmPC) of fosfomycin i.v.\n* Patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis\u002Fcentral nervous system infection, bacteraemia\u002Fsepsis, skin and soft tissue infection, endocarditis or other infection, each as far as covered by the respective nationally relevant SmPC\n* Written informed consent of the participant (or person in charge in case of patients incapable of giving consent)\n\nExclusion Criteria:\n\n* Previous documentation of the patient in the present study\n* Patients participating in an interventional clinical trial\n* Patients with known hypersensitivity to fosfomycin or any of the excipients\n* Terminally ill patients\n* Patients with \"do not resuscitate order\"\n* Palliative treatment approach\n* Failure of \\> 3 of the following organ systems: respiratory system, nervous system, cardiovascular system, liver, coagulation, kidney\n* Manifest Human Immunodeficiency Virus (HIV) disease (Acquired Immunodeficiency Syndrome, AIDS)\n* Fosfomycin treatment as 4th line treatment or at later stage\n* Patients with involvement of fungi or mycobacteria in the targeted infection",{"count":114,"type":21},1000,"The purpose of this European, multicentric, prospective, non-interventional study is to document and evaluate the efficacy and safety of the treatment of severely infected patients with intravenously administered fosfomycin, including patients with osteomyelitis, complicated urinary tract infection, nosocomial lower respiratory tract infection, bacterial meningitis\u002Fcentral nervous system infection, bacteraemia\u002Fsepsis, skin and soft tissue infection, endocarditis or other infections, each as far as covered by the respective nationally relevant SmPC.",[117,118,119,120,121,122,123,88,124,125,126,26,127,128,129,130],"Bacterial Infections","Bone Diseases, Infectious","Osteomyelitis","Central Nervous System Bacterial Infections","Meningitis, Bacterial","Encephalitis","Brain Abscess","Respiratory Tract Infections","Pneumonia, Bacterial","Skin Diseases, Bacterial","Intraabdominal Infections","Sepsis","Bacteremia","Endocarditis, Bacterial",[132,133,134,135,136,137,138,139,140,141,117,142,143,118,119,120,121,122,123,88,124,125,126,26,127,128,129,130,144,145,146,147],"Observational Study","Non-Interventional Study","Registries","Prospective","Monitored","Multicentric","International","Fosfomycin","Infectofos","Fomicyt","Gram-Negative Bacterial Infections","Gram-Positive Bacterial Infections","Treatment Outcome","Clinical Efficacy","Microbiological Efficacy","Safety","2024-09-27",{"date":150,"type":34},"2024-10-01",{"date":152,"type":4},"2016-12",{"date":154,"type":21},"2030-12",{"name":156,"class":157},"Infectopharm Arzneimittel GmbH","INDUSTRY",50]